Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1806 results
July 2018
-
Media ReleaseNovartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanomaPhase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo[1] Relapse-free survival benefit with…
-
Media ReleaseNovartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver flukeNovartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million…
-
Media ReleaseNovartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitisNovartis enters an exclusive license agreement with Galapagos and MorphoSys for an investigational biologic compound, MOR106, a novel antibody directed against IL-17C IL-17C is believed to…
-
Media ReleaseNovartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal womenKisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer…
-
Featured NewsNovartis Financial Results – Q2 2018Today, Novartis announced the company’s financial results for the second quarter and H1 of 2018.
-
Key ReleaseNovartis delivers solid growth in second quarter and continues transformation to a focused medicines companyNet sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD…
-
Key ReleaseNovartis réalise une solide croissance au deuxième trimestre et poursuit sa transformation en une entreprise axée sur les médicamentsHausse du chiffre d'affaires net de 5% (tcc[1], +7% USD), stimulée principalement par: Cosentyx, qui a progressé à USD 701 millions, (+40% tcc), enregistrant une forte croissance dans toutes ses…
-
Key ReleaseNovartis erzielt im zweiten Quartal ein solides Wachstum und setzt die Transformation zu einem fokussierten Arzneimittelunternehmen fortDer Nettoumsatz steigt um 5% (kWk[1], +7% USD), vor allem dank folgender Beiträge: Cosentyx erreicht USD 701 Millionen (+40% kWk) mit starken Zuwächsen bei allen Indikationen in den USA und der…
-
StatementEssential Consultants – Updates
-
Drug development gets big data analytics boost
With Nerve Live, Novartis is harnessing the power of data for the benefit of patients.
June 2018
-
Key ReleaseNovartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in EuropeFirst CHMP opinion for a CAR-T cell therapy in two distinct indications - DLBCL in adults and B-cell ALL in children Marketing Authorization Application (MAA) based on landmark global CAR-T…
-
Key ReleaseNovartis erhält positive CHMP-Stellungnahme für Kymriah® zur Behandlung zweier aggressiver Blutkrebsarten - ein wichtiger medizinischer Fortschritt für Patientinnen und Patienten in EuropaErste CHMP-Stellungnahme zu CAR-T-Zell-Therapie bei zwei verschiedenen Indikationen: DLBCL bei Erwachsenen und B-Zell-ALL bei Kindern Der Antrag auf Marktzulassung (MAA) basiert auf zwei…
Pagination
- ‹ Previous page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- …
- 151
- › Next page